Testing adebelizumab and irinotecan liposome for advanced small cell lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a combination of two drugs (adebelizumab and irinotecan liposome) for people with advanced small cell lung cancer that got worse after first-line treatment. It aims to see if this combination works better and to find out which patients benefit the most.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age between 18 and 75 years old.
- Diagnosed with small cell lung cancer (not the mixed type) that has gotten worse after first treatment that included chemo and immunotherapy.
- At least one tumor that can be measured on scans.
- Good overall health (able to do daily activities) with normal organ function (like blood counts, liver, and kidneys).
- No prior use of irinotecan or irinotecan liposome.
- No serious heart or lung disease, active infections, or other cancers in the last 5 years (except for certain cured ones).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of drugs (liposomal irinotecan plus others) as a first treatment for people with extensive-stage small cell lung cancer. It may offer a new approach if you haven't had any therapy yet.
This trial is testing a new form of chemotherapy called irinotecan liposomes for people with advanced small cell lung cancer that has worsened after initial treatment. It aims to see if this drug can shrink tumors and improve survival.
This trial tests a combination of a liposome-encased chemotherapy (irinotecan), a platinum drug, an immunotherapy, and a targeted therapy (anlotinib) as a maintenance treatment for extensive small cell lung cancer. The goal is to see if this approach helps keep the cancer from growing after initial successful treatment.
This study tests a drug called adebrelimab, used alone or with other treatments, for people with advanced solid tumors, including extensive-stage small cell lung cancer. It aims to see if adding this drug helps control the cancer.
This study is testing a new combination of two immunotherapy drugs (adebrelimab and vunakizumab) plus chemotherapy for people with previously untreated extensive-stage small cell lung cancer. The goal is to see if this approach helps shrink tumors and improves outcomes.
This trial tests a new immunotherapy drug called adebrelimab combined with standard chemotherapy and radiation for people with limited-stage small cell lung cancer. After the initial treatment, adebrelimab is continued alone to help prevent the cancer from coming back.
Hear when a new Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.